J.Molner AS (OTSE:MOLNR) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OTSE:MOLNR J.Molner AS OTSE:MOLNR
40 GF Score
Price €18.90
GF Value €19.62
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is J.Molner AS SpecialCharges?

Special Charges only applies to banks.

OTSE:MOLNR
40GF Score
J.Molner AS OTSE:MOLNR
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?

Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued. The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62. GuruFocus considers J.Molner AS to be Fairly Valued.

Key valuation signals for OTSE:MOLNR:

  • SpecialCharges:
  • GF Value™: €19.62 vs. price of €18.90 (3.7% below fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

J.Molner AS Business Description

Address Akadeemia tee 21/5, Harju maakond, Tallinn, EST, 12618
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score

Get the complete analysis for OTSE:MOLNR

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.90
Price
€19.62
GF Value